1189661-02-6
Chemical Structure
Carebastine-d5
- CAS No.: 1189661-02-6
- Formula:C32H32D5NO4
- Molecular Weight:504.67
IUPAC Name: 2-methyl-2-(4-(4-(4-(phenyl(phenyl-d5)methoxy)piperidin-1-yl)butanoyl)phenyl)propanoic acid
InChIKey: XGHOVGYJHWQGCC-KILXEUBNSA-N
SMILES: O=C(C1=CC=C(C=C1)C(C)(C)C(O)=O)CCCN(CC2)CCC2OC(C3=CC=CC=C3)C4=C([2H])C([2H])=C([2H])C([2H])=C4[2H]
Biological Activity: Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner[1]. Carebastine suppresses the expression of macrophage migration inhibitory factor[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carebastine-d5 | Carebastine-d5 is the deuterium labeled Carebastine. Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carebastine | 99.23% | Carebastine is an Ebastine (HY-B0674) metabolite and H1-receptor antagonist. Carebastine inhibits VEGFR-2 and Akt phosphorylation. Carebastine exerts an anti-inflammatory effect by inhibiting MIF as well as TNF-α and IL-6 production. Carebastine shows anti-angiogenic activity | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. De Luisi A, et al. Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling. Eur Respir J. 2009 Oct;34(4):958-66. [Content Brief]
